KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) FCF Margin (2017 - 2025)

Bionano Genomics (BNGO) has disclosed FCF Margin for 9 consecutive years, with 51.57% as the latest value for Q4 2025.

  • Quarterly FCF Margin rose 2811.0% to 51.57% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 57.18% through Dec 2025, up 16710.0% year-over-year, with the annual reading at 57.18% for FY2025, 16710.0% up from the prior year.
  • FCF Margin hit 51.57% in Q4 2025 for Bionano Genomics, up from 80.75% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 42.81% in Q1 2025 to a low of 585.08% in Q1 2022.
  • Historically, FCF Margin has averaged 301.0% across 5 years, with a median of 321.58% in 2021.
  • Biggest five-year swings in FCF Margin: soared 28859bps in 2021 and later tumbled -14619bps in 2022.
  • Year by year, FCF Margin stood at 416.69% in 2021, then dropped by -5bps to 439.05% in 2022, then surged by 34bps to 289.49% in 2023, then soared by 72bps to 79.68% in 2024, then skyrocketed by 35bps to 51.57% in 2025.
  • Business Quant data shows FCF Margin for BNGO at 51.57% in Q4 2025, 80.75% in Q3 2025, and 51.79% in Q2 2025.